# Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

> **NCT06339788** · PHASE1 · COMPLETED · sponsor: **Handok Inc.** · enrollment: 40 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** HD-P023
- **DRUG:** Teneligliptin
- **DRUG:** Empagliflozin

## Key facts

- **NCT ID:** NCT06339788
- **Lead sponsor:** Handok Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-10
- **Primary completion:** 2024-06-12
- **Final completion:** 2024-06-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06339788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06339788, "Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06339788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*